Gland Pharma Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1788.70 +10.25 (0.58%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1727.85
Today’s High
1791.9
52 Week Low
1590
52 Week High
2220.95
1785.50 +2.50 (0.14%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1725
Today’s High
1794
52 Week Low
1585.7
52 Week High
2220.95
Key Metrics
- Market Cap (In Cr) 29375.23
- Beta 0.64
- Div. Yield (%) 1.12
- P/B 3.37
- TTM P/E 42.77
- Peg Ratio -4.53
- Sector P/E 31.15
- D/E 0.04
- Open Price 1747.35
- Prev Close 1778.45
Gland Pharma Analysis
Price Analysis
-
1 Week-1.93%
-
3 Months-7.61%
-
6 Month-0.99%
-
YTD-7.35%
-
1 Year9.44%
Risk Meter
- 32% Low risk
- 32% Moderate risk
- 32% Balanced Risk
- 32% High risk
- 32% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 3
- 3
- Buy
- 0
- 0
- 0
- 1
- Hold
- 1
- 1
- 1
- 1
- Sell
- 4
- 4
- 4
- 3
- Strong Sell
- 1
- 1
- 2
- 3
- Total
- 10
- 10
- 10
- 11
Gland Pharma News
Q2 Results today: IRCTC, IRFC, Amara Raja, Raymond, Bata India, and more
1 min read . 04 Nov 2024Gland Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 5664.72
- Selling/ General/ Admin Expenses Total
- 1486.88
- Depreciation/ Amortization
- 344.57
- Other Operating Expenses Total
- 671.68
- Total Operating Expense
- 4676.22
- Operating Income
- 988.51
- Net Income Before Taxes
- 1132.54
- Net Income
- 772.46
- Diluted Normalized EPS
- 46.89
- Period
- 2024
- Total Assets
- 10661.25
- Total Liabilities
- 1937.4
- Total Equity
- 8723.84
- Tangible Book Valueper Share Common Eq
- 508.13
- Period
- 2024
- Cashfrom Operating Activities
- 996.8
- Cashfrom Investing Activities
- -1756.91
- Cashfrom Financing Activities
- -799.42
- Net Changein Cash
- -1551.81
- Period
- 2023
- Total Revenue
- 3624.6
- Selling/ General/ Admin Expenses Total
- 810
- Depreciation/ Amortization
- 146.74
- Other Operating Expenses Total
- 9.73
- Total Operating Expense
- 2802.95
- Operating Income
- 821.65
- Net Income Before Taxes
- 1054.58
- Net Income
- 781.04
- Diluted Normalized EPS
- 50.26
- Period
- 2023
- Total Assets
- 8777.54
- Total Liabilities
- 818.81
- Total Equity
- 7958.72
- Tangible Book Valueper Share Common Eq
- 482.51
- Period
- 2023
- Cashfrom Operating Activities
- 363.97
- Cashfrom Investing Activities
- 1208.19
- Cashfrom Financing Activities
- 14.92
- Net Changein Cash
- 1590.08
- Period
- 2022
- Total Revenue
- 4400.71
- Selling/ General/ Admin Expenses Total
- 694.61
- Depreciation/ Amortization
- 110.3
- Other Operating Expenses Total
- 3.78
- Total Operating Expense
- 3000.67
- Operating Income
- 1400.03
- Net Income Before Taxes
- 1618.55
- Net Income
- 1211.66
- Diluted Normalized EPS
- 73.65
- Period
- 2022
- Total Assets
- 7833.62
- Total Liabilities
- 676
- Total Equity
- 7157.62
- Tangible Book Valueper Share Common Eq
- 434.87
- Period
- 2022
- Cashfrom Operating Activities
- 790.77
- Cashfrom Investing Activities
- -1002.62
- Cashfrom Financing Activities
- 34.9
- Net Changein Cash
- -173.64
- Period
- 2021
- Total Revenue
- 3462.88
- Selling/ General/ Admin Expenses Total
- 590.16
- Depreciation/ Amortization
- 98.78
- Other Operating Expenses Total
- 0.12
- Total Operating Expense
- 2259.43
- Operating Income
- 1203.45
- Net Income Before Taxes
- 1334.81
- Net Income
- 996.96
- Diluted Normalized EPS
- 62.99
- Period
- 2021
- Total Assets
- 6496.08
- Total Liabilities
- 592.84
- Total Equity
- 5903.24
- Tangible Book Valueper Share Common Eq
- 360.85
- Period
- 2021
- Cashfrom Operating Activities
- 604.93
- Cashfrom Investing Activities
- -1524
- Cashfrom Financing Activities
- 1238.46
- Net Changein Cash
- 322.97
- Period
- 2020
- Total Revenue
- 2633.24
- Selling/ General/ Admin Expenses Total
- 514.31
- Depreciation/ Amortization
- 94.59
- Other Operating Expenses Total
- 4.31
- Total Operating Expense
- 1772.36
- Operating Income
- 860.88
- Net Income Before Taxes
- 992.87
- Net Income
- 772.86
- Diluted Normalized EPS
- 46.5
- Period
- 2020
- Total Assets
- 4086.04
- Total Liabilities
- 439.8
- Total Equity
- 3646.23
- Tangible Book Valueper Share Common Eq
- 223.31
- Period
- 2020
- Cashfrom Operating Activities
- 700.94
- Cashfrom Investing Activities
- -766.08
- Cashfrom Financing Activities
- -6.87
- Net Changein Cash
- -66.9
- Period
- 2019
- Total Revenue
- 2044.2
- Selling/ General/ Admin Expenses Total
- 432.64
- Depreciation/ Amortization
- 82.12
- Other Operating Expenses Total
- 1.04
- Total Operating Expense
- 1439.82
- Operating Income
- 604.38
- Net Income Before Taxes
- 686.28
- Net Income
- 451.86
- Diluted Normalized EPS
- 28.48
- Period
- 2019
- Total Assets
- 3523.55
- Total Liabilities
- 661.55
- Total Equity
- 2862
- Tangible Book Valueper Share Common Eq
- 175.28
- Period
- 2019
- Cashfrom Operating Activities
- 185.26
- Cashfrom Investing Activities
- -314.14
- Cashfrom Financing Activities
- -3.12
- Net Changein Cash
- -136.44
- Period
- 2018
- Total Revenue
- 1622.89
- Selling/ General/ Admin Expenses Total
- 340.2
- Depreciation/ Amortization
- 78.37
- Other Operating Expenses Total
- 1.62
- Total Operating Expense
- 1165.98
- Operating Income
- 456.92
- Net Income Before Taxes
- 501.46
- Net Income
- 321.05
- Diluted Normalized EPS
- 21.33
- Period
- 2018
- Total Assets
- 2929.47
- Total Liabilities
- 519.11
- Total Equity
- 2410.36
- Tangible Book Valueper Share Common Eq
- 147.62
- Period
- 2018
- Cashfrom Operating Activities
- 202.11
- Cashfrom Investing Activities
- -358.84
- Cashfrom Financing Activities
- -3.77
- Net Changein Cash
- -160.24
- Period
- 2024-09-30
- Total Revenue
- 1405.83
- Selling/ General/ Admin Expenses Total
- 375.18
- Depreciation/ Amortization
- 93.83
- Other Operating Expenses Total
- 158.13
- Total Operating Expense
- 1202.6
- Operating Income
- 203.23
- Net Income Before Taxes
- 256.78
- Net Income
- 163.53
- Diluted Normalized EPS
- 9.93
- Period
- 2024-09-30
- Total Assets
- 10866.89
- Total Liabilities
- 2078.89
- Total Equity
- 8788
- Tangible Book Valueper Share Common Eq
- 511.24
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 643.63
- Cashfrom Investing Activities
- 2212.64
- Cashfrom Financing Activities
- -402.74
- Net Changein Cash
- 2463.02
- Period
- 2024-06-30
- Total Revenue
- 1401.71
- Selling/ General/ Admin Expenses Total
- 402.04
- Depreciation/ Amortization
- 91.96
- Other Operating Expenses Total
- 171.01
- Total Operating Expense
- 1229.28
- Operating Income
- 172.44
- Net Income Before Taxes
- 218.24
- Net Income
- 143.76
- Diluted Normalized EPS
- 8.73
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1537.45
- Selling/ General/ Admin Expenses Total
- 409.49
- Depreciation/ Amortization
- 92.61
- Other Operating Expenses Total
- 169.93
- Total Operating Expense
- 1271.41
- Operating Income
- 266.04
- Net Income Before Taxes
- 298.23
- Net Income
- 192.42
- Diluted Normalized EPS
- 11.68
- Period
- 2024-03-31
- Total Assets
- 10661.25
- Total Liabilities
- 1937.4
- Total Equity
- 8723.84
- Tangible Book Valueper Share Common Eq
- 508.13
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 996.8
- Cashfrom Investing Activities
- -1756.91
- Cashfrom Financing Activities
- -799.42
- Net Changein Cash
- -1551.81
- Period
- 2023-12-31
- Total Revenue
- 1545.16
- Selling/ General/ Admin Expenses Total
- 409.36
- Depreciation/ Amortization
- 105.34
- Other Operating Expenses Total
- 180.16
- Total Operating Expense
- 1294.11
- Operating Income
- 251.05
- Net Income Before Taxes
- 283.16
- Net Income
- 191.86
- Diluted Normalized EPS
- 11.65
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 1373.42
- Selling/ General/ Admin Expenses Total
- 363.23
- Depreciation/ Amortization
- 81.3
- Other Operating Expenses Total
- 164.55
- Total Operating Expense
- 1130.64
- Operating Income
- 242.78
- Net Income Before Taxes
- 289.89
- Net Income
- 194.08
- Diluted Normalized EPS
- 11.78
- Period
- 2023-09-30
- Total Assets
- 10292.84
- Total Liabilities
- 1986.13
- Total Equity
- 8306.71
- Tangible Book Valueper Share Common Eq
- 467.34
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 421.77
- Cashfrom Investing Activities
- -1049.76
- Cashfrom Financing Activities
- -801.05
- Net Changein Cash
- -1428.08
- Period
- 2023-06-30
- Total Revenue
- 1208.69
- Selling/ General/ Admin Expenses Total
- 304.8
- Depreciation/ Amortization
- 65.32
- Other Operating Expenses Total
- 157.04
- Total Operating Expense
- 980.05
- Operating Income
- 228.64
- Net Income Before Taxes
- 261.27
- Net Income
- 194.1
- Diluted Normalized EPS
- 11.78
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 785.01
- Selling/ General/ Admin Expenses Total
- 132.33
- Depreciation/ Amortization
- 37.54
- Other Operating Expenses Total
- 119.42
- Total Operating Expense
- 710.6
- Operating Income
- 74.41
- Net Income Before Taxes
- 111.15
- Net Income
- 78.68
- Diluted Normalized EPS
- 7.19
- Period
- 2023-03-31
- Total Assets
- 8777.54
- Total Liabilities
- 818.81
- Total Equity
- 7958.72
- Tangible Book Valueper Share Common Eq
- 482.51
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 363.97
- Cashfrom Investing Activities
- 1208.19
- Cashfrom Financing Activities
- 14.92
- Net Changein Cash
- 1590.08
- Period
- 2022-12-31
- Total Revenue
- 938.29
- Selling/ General/ Admin Expenses Total
- 130.35
- Depreciation/ Amortization
- 37.61
- Other Operating Expenses Total
- 91.3
- Total Operating Expense
- 686.33
- Operating Income
- 251.96
- Net Income Before Taxes
- 310.85
- Net Income
- 231.95
- Diluted Normalized EPS
- 14.08
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Gland Pharma Technical
Moving Average
SMA
- 5 Day1765.78
- 10 Day1771.32
- 20 Day1704.17
- 50 Day1756.49
- 100 Day1853.69
- 300 Day1839.1
Gland Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Syngene International
- 847.65
- -2.6
- -0.31
- 945.75
- 608
- 33971.38
- Suven Pharmaceuticals
- 1276
- -3.5
- -0.27
- 1358.75
- 578.05
- 32482.49
- Gland Pharma
- 1788.7
- 10.25
- 0.58
- 2220.95
- 1590
- 29461.77
- Laurus Labs
- 489.25
- 0.1
- 0.02
- 517.9
- 358.7
- 26368.9
- JB Chemicals & Pharmaceuticals
- 1715
- 49.1
- 2.95
- 2029
- 1376.95
- 26617.05
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Syngene International
- 65.62
- 8.01
- 14.56
- 16.22
- Suven Pharmaceuticals
- 107.58
- 15.88
- 27.91
- 33.21
- Gland Pharma
- 38.03
- 3.37
- 14.89
- 22.92
- Laurus Labs
- 162.98
- 6.41
- 20.68
- 12.83
- JB Chemicals & Pharmaceuticals
- 47.82
- 8.85
- 20.54
- 16.06
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 04-Nov-24
- Quarterly Results
- 06-Aug-24
- Quarterly Results
- 22-May-24
- Audited Results & Final Dividend
- 14-Feb-24
- Quarterly Results
- 06-Nov-23
- Quarterly Results
- 07-Aug-23
- Quarterly Results
- 18-May-23
- Audited Results & A.G.M.
- 23-Jan-23
- Quarterly Results
- 26-Oct-22
- Quarterly Results
- 20-Jul-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 30-Aug-24
- 22-May-24
- AGM
- 20-Nov-23
- 19-Oct-23
- POM
- 31-Aug-23
- 01-Aug-23
- AGM
- 08-Mar-23
- 06-Feb-23
- POM
- 30-Aug-22
- 19-May-22
- AGM
- 22-Apr-22
- 21-Mar-22
- POM
- 26-Aug-21
- 17-May-21
- AGM
- 21-Sept-20
- 25-Aug-20
- AGM
- 30-Sept-19
- 29-Aug-19
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 22-May-24
- 16-Aug-24
- 16-Aug-24
- 20